ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 706

Elevated Erythrocyte Sedimentation Rate Among Obese Patients with SLE- Not Always a Marker of Disease Activity

George Stojan1, Erik Barr2 and Michelle Petri3, 1Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, 3Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Obesity and systemic lupus erythematosus (SLE), SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Obesity is more common in patients with SLE compared to the general population. The prevalence of obesity among SLE patients is between 28 and 50 percent. We hypothesized that a higher body mass index was associated with elevated ESR after adjusting for disease activity, prednisone and immunosuppressive use.

Methods:

Our analysis is based on 2246 different patients who were observed from 1 to 137 visits. The median number of visits per patient was 15.

The “between-person” association addresses the question of whether those who tend to have high BMI also tend to have high ESR. To assess this, we calculated the person-specific mean ERS values and plotted them against the person-specific mean BMIs. \We fit crude and adjusted models to estimate the slope in the expectation of mean ESR per unit difference in mean BMI. The results are shown in Table 1.

The within-person analysis addresses the question of whether a person tends to have higher ESR when his/her BMI is lower than his average BMI. To assess this, for each visit, we calculated the difference between the BMI level at that visit and the person’s average of BMI. Then we modelled the relationship between these differences in BMI and the difference between the person’s ESR at each visit and the person’s average ESR.

Results:

Table 1: Difference in person-specific mean ESR per 1 unit difference in person-specific mean BMI

Model

Effect

Unadjusted

Adjusted1

Estimated difference in mean ESR per 1 unit difference in mean BMI (95% CI)

P-value

Estimated difference in mean ESR per 1unit difference in mean BMI (95% CI)

P-value

Model 1

Pooling across Sex

BMI

0.6 (0.4, 0.7)

<0.0001

0.5 (0.4, 0.6)

<0.0001

Model 2

Allowing different association by sex

BMI

0.6 (0.5, 0.7)

<0.0001

0.5 (0.4, 0.7)

<0.0001

Female

5.0 (-12.2, 22.2)

0.57

3.2 (-12.1, 18.5)

0.68

BMI*Sex

-0.5 (-1.1, 0.2)

0.14

-0.3 (-0.9, 0.2)

0.24

1 Adjusted for age, age-squared, race, mean disease activity, mean prednisone dose, proportion of time on immunosuppressant medication.

Table 2: Difference in ESR at each visit per 1 unit difference in between the person’s BMI at that visit and the person’s average BMI.

Model

Effect

Unadjusted

Adjusted1

Estimated difference in ESR (relative to a person’s average ESR) as a function of differences in a person’s BMI (relative to that person’s average BMI)

P-value

Estimated difference in ESR (relative to a person’s average ESR) as a function of differences in a person’s BMI (relative to that person’s average BMI)

P-value

Model 1: Pooling across Sex

BMI -mean BMI

0.04 (-0.01, 0.10)

0.15

0.09 (0.03, 0.15)

0.004

Model 2

Allowing different association by sex

BMI -mean BMI

0.05 (-0.01, 0.11)

0.12

0.09 (0.03, 0.15)

0.004

Females

0.004 (-0.54, 0.54)

0.99

0.26 (-0.30, 0.82)

0.36

BMI -mean BMI *Sex

-0.07 (-0.31, 0.16)

0.55

-0.04 (-0.28, 0.21)

0.78

1 Adjusted for age, age-squared, race, disease activity, prednisone dose, immunosuppressant use.

Conclusion:

Patients whose mean BMI is 10 points higher have a mean ESR that is 6mm/hour higher (p<0.0001). The association between BMI and ESR does not vary by sex and is not affected by adjusting for covariates.

We also found a significant within person association between ESR and BMI: a 1 unit increase in BMI increases the expected ESR by 0.09mm/hour (p=0.004).

Careful interpretation of clinical data is necessary in obese patients- an elevated ESR may not be a manifestation of disease activity.


Disclosure: G. Stojan, None; E. Barr, None; M. Petri, Anthera Inc, 5,GlaxoSmithKline, 5,EMD Serono, 5,Eli Lilly and Company, 5,Bristol Meyer Squibb, 5,Amgen, 5,United Rheumatology, 5,Global Academy, 5,Exagen, 2.

To cite this abstract in AMA style:

Stojan G, Barr E, Petri M. Elevated Erythrocyte Sedimentation Rate Among Obese Patients with SLE- Not Always a Marker of Disease Activity [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/elevated-erythrocyte-sedimentation-rate-among-obese-patients-with-sle-not-always-a-marker-of-disease-activity/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-erythrocyte-sedimentation-rate-among-obese-patients-with-sle-not-always-a-marker-of-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology